Clinical trial
A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia
NCT00333307 is registered in ClinicalTrials.gov with Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia
- Lead sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
- Phase
- Phase 1
- Overall status
- Suspended
- Start date
- October 31, 2006
- Completion date
- Not reported
- Enrollment
- 18 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.